The Ministry of Healthcare announced that prices for several pharmaceutical lines dropped multifold.
Reductions were achieved through direct manufacturer contracts, intermediary exclusions, corporate pharmaceutical negotiations, international procurement, and competitive auctions.
Following the 2026 procurement campaign, the combined economic return reached 70 billion tenge. Sourcing directly from domestic and international manufacturers generated roughly...
